[Clinical response to de-nol in peptic ulcer patients].
In treatment 60 patients with duodenal and stomach peptic ulcer in composition standard eradication therapy was used de-nol. Thus, along with the positive dynamics of clinical symptoms of disease, there is renewal of motor activity of stomach, improvement of microcirculation and renewal of protective properties of gastric mucus. There is a decline of frequency of relapses of disease from data of remote supervisions on a background high-quality reparation of ulcerous defect at the used of de-nol.
Afanas'eva
T S
TS
Perevozshchikova
E E
EE
Vakhrushev
Ia M
IaM
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D006801:Humans; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D055502:Secondary Prevention; D016896:Treatment Outcome; D055815:Young Adult
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; C002791:bismuth tripotassium dicitrate